TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Withdrawal Symptoms (MNWS Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Urges (BQSU Factor 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Choice Paradigm: Amount Earned ($)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Grad 4 Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Bone Mineral Density of the Lumbar Spine at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Bone Mineral Density of the Total Hip Region at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Salivary Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Participants with Solicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from device-related or procedure-related death
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from stroke
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from annulus rupture, coronary occlusion, ventricular perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Kilocalorie Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum drug concentration (Cmax) of lacosamide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from 0 to the time of the last quantifiable concentration (AUC(0-t)) of lacosamide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from 0 to infinity (AUC) of lacosamide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of Direct Hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: sustained pain free response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life at 2 years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Activation of brain areas in self body-recognition network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of retrieved oocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Outcomes of therapy with Sofosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Documented Follow-up of a Red Flag Suggestive of Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effectiveness of the PillCam COLON 2 Bowel Prep Regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mediastinal blood drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Post-operative Nausea and/or Vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Mean number of intravitreal aflibercept injections in 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects receiving 0 aflibercept injections in 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-Day survival
Endpoint domain: Mortality/survival
Primary endpoint: number of circulating endothelial cells (CECs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of endothelial progenitor cells (EPCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychosocial Impact
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MRI Arterial Spin Labeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic potential of plasma procalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in mean amplitude of glycemic excursion (MAGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Posttreatment tumor to non-tumor activity concentration ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Emotional Stroop performance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Over-selectivity task performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of glaucoma following congenital cataracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Change in Post-natal depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Consistency in condom use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: number of cerebrospinal fluid (CSF) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of patients with grade 3 or higher neurological adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the serum concentration time curve (AUC0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average serum concentration 0-24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to achieve maximum serum concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Conversion to Cystic Fibrosis Related Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Accuracy of Factor Xa and Thrombin Inhibitors Pads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum culture conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum Hemagglutination Inhibition (HI) Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seropositive Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Seroconverted for HI Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HAMD (Hamilton Depression Rating Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTc (Corrected QT Interval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of augmented renal clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pathological diagnosis of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of the tissue sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inducibility and plasticity of brown adipose tissue activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Major and Clinically Relevant Non Major bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: steady state pharmacokinetics (AUC) of methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Central Subfield Thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Visual Acuity Letter Score at Each Follow-up Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CMV Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frenchay Arm Test (FAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With a Mean Treatment Interval Between Injections of ≥ 8 Weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Assessment of physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery-Aspberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Curve (AUC) From Day 0 to Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distress agreement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of the initial hospitalization (days)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Area under the curve (AUC) of serum aspartate transaminase (AST) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of avoidable ED visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence rate of avoidable InstaCare visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Successful LMA insertion at first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with hematopoietic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with Symptomatic lymphocele
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Z-score of the DXA scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCO2 decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Best of Response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instrumental extraction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Primary and secondary implant stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: opioid disposal rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Vital status at birth
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between multiple EyeArt operations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection with Chlamydia trachomatis
Endpoint domain: Adverse events/effects
Primary endpoint: Class Attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Satisfaction With the Randomized Controlled Trial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Photosensitizer Uptake and Conversion to Protoporphyrin IX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of 633 nm Red Light
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Bond and Lader Visual Analogue Scale (BL-VAS) at 2 Hours Post Dose
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Identification of Extra Cellular RNAs/proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to first documented clinical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of potentially clinically significant abnormalities in clinical laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time interval between end of surgery and first void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in eustachian tube function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma beta-amyloid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIT Kit Return at 6 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Colonoscopy Ordered at 6 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Motor Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dermal sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Toxicity of Rituximab
Endpoint domain: Adverse events/effects
Primary endpoint: end-stage renal disease
Endpoint domain: Mortality/survival
Primary endpoint: white blood cell count(10^9 /L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: C-reactive protein(mg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech Intelligibility Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with cavitary lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RSV Viral Load-time Curve (AUC [Day 1-5])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in neurological performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinically significant changes in physical examinations, laboratory safety tests, and vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conditioned Eyeblink Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of time in normal glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to first clinical worsening event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Central Apnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Distribution of the Last Interval With no Disease Activity up to Week 32
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change From Baseline at Week 28 and Week 32 in Best-corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Cerebral Desaturation Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perceived quality of life by EQ-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma concentrations of simvastatin and simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CPR quality (compressions rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CPR quality (compressions depth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in emergency level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance with feeding recommendation
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Serum Cotinine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of SNPs or genetic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Computed FFR values compared to real FFR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endocannabinoid plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the characteristics and degree of discomfort of xerostomia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concurrent validity of Autocad software
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oxygen Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dependence after stroke
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hormonal Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Psychosocial Adversity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychosocial Health Risk Factors Correlated With BMI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Social Adjustment Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: integrated measure of thinking while walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Individual well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in plaque elevation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in C-reactive Protein (C-RP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Tumor Necrosis Factor-alpha (TNF-a) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Interleukin-6 (IL-6) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Interleukin-8 (IL-8) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bourban trunk muscle strength (TMS) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients with at least 30% pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in symptoms of Carpal Tunnel Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritability / Agitation measured by ABC-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eradication rate of small intestinal bacterial overgrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in dyskinesia severity and duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: all cause intra-ICU mortality
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of First Complete Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occurrence of First Partial Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Required CathFlo (Alteplase) to Resolve an Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visuospatial Problem Solving Battery (VSP)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: melatonin levels in PPROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soluble urokinase-type plasminogen activator receptor levels in PPROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: orosomucoid 2 levels in PPROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lag time of the thrombin generation curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Postoperative Staphylococcus (S.) Aureus Bloodstream Infection (BSI) And/or Surgical-site Infection (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Systemic Reactions Within 10 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: IMA Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic AUC value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Anti-HPV antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incontinence severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glabellar line improvement rate at maximum frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Helicobacter Pylori Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients within optimal P2Y12 inhibition window
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Response Rate (Patients That Achieve a CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in PTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes